- Price caps on essential cancer drugs aim to curb exorbitant costs and improve affordability for patients. - High out-of-pocket expenditure on oncology treatment remains a major driver of catastrophic health expenditure and impoverishment in India. - Structural challenges like trade margins, supply chain markups, and substitution by non-capped or newer patented drugs can limit the overall impact of price controls. - A comprehensive approach involving price capping, promotion of generics, strengthening public health infrastructure, and strategic government procurement is necessary to truly reduce cancer treatment costs. - **National Pharmaceutical Pricing Authority:** An expert regulatory body established by the Government of India in 1997 to fix and revise prices of pharmaceutical products and enforce the Drugs (Prices Control) Order. - **Drugs (Prices Control) Order:** A statutory order issued by the central government under the Essential Commodities Act to regulate the prices of essential medicines and curb profiteering. - **National List of Essential Medicines:** A curated compilation of medicines considered fundamental to basic healthcare needs, prioritizing public health relevance, cost, and safety. **Introduction** The article examines whether imposing price caps on cancer drugs effectively brings down the overall cost of treatment in India. While price caps by regulatory bodies like the NPPA help reduce the direct cost of specific essential medicines, out-of-pocket expenses remain high due to complex treatment cycles, diagnostics, hospitalization, and the prevalence of non-regulated therapies or newer patented alternatives. The analysis highlights the necessity of multi-pronged policy measures to address cancer care affordability comprehensively. **Core Issue and Detailed Points** - Price caps on essential cancer drugs aim to curb exorbitant costs and improve affordability for patients. - High out-of-pocket expenditure on oncology treatment remains a major driver of catastrophic health expenditure and impoverishment in India. - Structural challenges like trade margins, supply chain markups, and substitution by non-capped or newer patented drugs can limit the overall impact of price controls. - A comprehensive approach involving price capping, promotion of generics, strengthening public health infrastructure, and strategic government procurement is necessary to truly reduce cancer treatment costs. **Key Statutory Bodies, Acts & Concepts** - **National Pharmaceutical Pricing Authority:** An expert regulatory body established by the Government of India in 1997 to fix and revise prices of pharmaceutical products and enforce the Drugs (Prices Control) Order. - **Drugs (Prices Control) Order:** A statutory order issued by the central government under the Essential Commodities Act to regulate the prices of essential medicines and curb profiteering. - **National List of Essential Medicines:** A curated compilation of medicines considered fundamental to basic healthcare needs, prioritizing public health relevance, cost, and safety.